GLP-1 Drugs and Your Employee Health Plan: What Employers with 20 to 250 Employees Need to Know in 2026

GLP-1 medications have moved from specialty pharmacy footnote to one of the fastest-growing line items on employer health plan budgets. Drugs like semaglutide and tirzepatide were originally approved for type 2 diabetes, but their dramatic weight loss results pushed demand far beyond the diabetic population. For mid-size employers, that shift happened quickly, and many found out at renewal instead of ahead of it.

If you run a company with 20 to 250 employees, you are not insulated from this. Your plan is smaller, which means a handful of high-cost claimants can move your renewal number in ways that would barely register at a Fortune 500. One employee on a GLP-1 drug for weight management can cost your plan 500 to 700 dollars per month, every month, indefinitely. Multiply that across even three or four employees and you are looking at a material claims increase before your next renewal conversation.

This article breaks down what GLP-1 drugs actually cost a health plan, how carriers and stop-loss providers are responding, and the three practical approaches mid-size employers are using right now to manage coverage without cutting benefits people actually value.

What GLP-1 Medications Are and Why Employers Are Paying Attention

The Drug Class That Changed the Obesity Conversation

GLP-1 stands for glucagon-like peptide-1 receptor agonist. That is a mouthful, but the mechanism is straightforward: these drugs mimic a hormone that regulates blood sugar and appetite. Originally developed and FDA-approved for type 2 diabetes management, the GLP-1 class expanded significantly when clinical trials showed average body weight reductions of 15 to 22 percent in participants using them for obesity.

The most recognized names are semaglutide (sold as Ozempic for diabetes and Wegovy for weight management) and tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight management). Both are weekly injectable medications. Both carry the same list price regardless of which condition they are prescribed for. And both are showing up in employer health plan claims data at a rate that caught most benefits managers off guard.

According to the KFF 2024 Employer Health Benefits Survey, the share of employers actively tracking GLP-1 claims as a distinct budget line has grown sharply over the past two renewal cycles. That tracking is happening because the cost signal is hard to ignore.

For employers, the distinction between the diabetes indication and the obesity indication matters enormously from a coverage and cost management standpoint. A plan that covers GLP-1 drugs for diabetes only is covering a medically necessary treatment for a chronic condition. A plan that also covers GLP-1 drugs for weight management opens coverage to a much larger eligible population, and the cost trajectory looks very different.

What These Medications Cost a Health Plan

List prices for GLP-1 medications range from roughly 900 to 1,400 dollars per month per member. After manufacturer rebates and pharmacy benefit manager (PBM) negotiated pricing, the net plan cost typically lands in the 400 to 700 dollar range per member per month, depending on your plan's PBM contract and formulary tier placement.

That is not a one-time cost. GLP-1 drugs, particularly for weight management, are generally continued long-term. Clinical data shows that patients who stop taking GLP-1 medications for obesity regain a significant portion of lost weight within a year. That creates a dynamic where covering the drug means covering it indefinitely for many members.

For a 150-person employer group, if 4 to 6 percent of covered members are on a GLP-1 drug for weight management at any given time, the plan is absorbing 36,000 to 63,000 dollars per year in pharmacy claims just from that drug class. If utilization climbs to 8 or 10 percent, which some actuarial projections consider plausible by 2027, that number roughly doubles.

Milliman actuarial research has modeled GLP-1 cost trajectories extensively, and the consistent finding is that mid-size self-funded plans without explicit GLP-1 cost management strategies are at meaningful financial risk at renewal if utilization accelerates. The math is not complicated: a few high-frequency, high-cost claimants in a small pool moves the claims experience faster than any other single drug category.

How Carriers Are Handling GLP-1 Coverage Right Now

The Three Tiers of Carrier Coverage Policy

If you are fully insured, your carrier controls how GLP-1 drugs are handled in your benefit design. And right now, carriers are not uniform about it. There are roughly three approaches in the market.

The first approach is coverage for diabetes only. Under this structure, GLP-1 drugs are covered when prescribed for type 2 diabetes management, but the plan explicitly excludes weight-loss indication coverage. The member may still get the drug if they have a diabetes diagnosis, but a prescription for obesity alone does not trigger a covered benefit. This is the most cost-contained option, and it keeps GLP-1 access focused on the population where the clinical case was originally strongest.

The second approach is coverage for both diabetes and obesity with prior authorization. The plan covers GLP-1 drugs across both indications, but requires a documented approval process before dispensing. Prior authorization typically requires the prescribing physician to verify diagnosis, confirm the member has a qualifying BMI (usually 30 or higher, or 27 or higher with a comorbidity), and document that other interventions have been attempted. This gates access without eliminating it.

The third approach is broad formulary inclusion with standard cost-sharing. Some carriers, particularly those in competitive markets, have included GLP-1 drugs on standard formulary tiers with co-pay or standard cost-sharing. This generates the lowest friction for members but the highest cost exposure for the plan. Some carriers in this category have already announced formulary adjustments for 2026 renewals because the claims volume outpaced their actuarial assumptions.

What Happens at Renewal When GLP-1 Claims Spike

If your group has had significant GLP-1 utilization in the prior plan year, it shows in your claims experience. For fully insured small and mid-size groups, that experience feeds directly into your renewal rating. You may see your broker present a renewal increase and then bury GLP-1 pharmacy as one line in a claims summary that is easy to miss.

Ask for it explicitly. Request a pharmacy claims breakdown at renewal that separates GLP-1 drugs by indication if your PBM captures that data. You want to know: how many unique members used a GLP-1 drug, what the average monthly cost per member was, and whether the indication was primarily diabetes or weight management.

Understanding your plan's loss ratio going into renewal gives you leverage. If GLP-1 claims are driving a deteriorating loss ratio but the rest of your plan is running clean, that is a negotiating point. You can address the GLP-1 exposure specifically through benefit design changes rather than accepting a blanket rate increase.

Who Is Using GLP-1 Medications in Your Plan (and How to Assess Your Exposure)

Workforce Demographics and GLP-1 Risk

GLP-1 exposure correlates with workforce demographics. Plans with a higher proportion of employees between ages 35 and 65, particularly those with conditions like type 2 diabetes, hypertension, or obesity, carry more GLP-1 risk. This is not a judgment on your workforce; it is just actuarial reality. The drugs were developed for conditions that are more prevalent in middle age and beyond.

Industry also matters. Sedentary industries like office-based financial services or technology tend to see higher GLP-1 uptake than physically active workforces in construction or skilled trades. That is partly because office workers have different health profiles and partly because employer-sponsored coverage in those sectors tends to have more generous pharmacy benefits to start with.

If you have never run a biometric screening or health risk assessment on your workforce, this is a moment where that data would be genuinely useful. You do not need to know individual diagnoses, but aggregate data about BMI distribution or diabetes prevalence in your enrolled population helps your broker and benefits consultant size your GLP-1 exposure realistically. Most PEO arrangements or self-funded plan designs allow for this type of aggregate reporting without creating privacy issues.

How Stop-Loss Carriers Are Adjusting to This

For self-funded and level-funded employers, stop-loss coverage is what protects you from catastrophic individual claims. Historically, stop-loss carriers set specific attachment points (the threshold above which they reimburse) and applied them fairly broadly. GLP-1 drugs are changing that calculation.

Several stop-loss carriers have added specific contract language for GLP-1 coverage. Some are carving out GLP-1 weight-loss claims entirely, meaning those costs do not count toward the individual stop-loss attachment point and are 100 percent the employer's exposure. Others are raising individual attachment points to account for the new cost base. A few are adding laser provisions on specific members who are already on high-cost GLP-1 regimens at the time of renewal.

This matters because the traditional assumption that catastrophic stop-loss protects you from runaway pharmacy costs may not hold as clearly as it once did. If your stop-loss contract excludes GLP-1 weight-loss indications, you are fully exposed on those claims regardless of how high they go. Before your next stop-loss renewal, have your broker pull the specific GLP-1 language and walk you through it line by line.

Three Practical Approaches Mid-Size Employers Are Taking

Approach 1: Cover for Diabetes Only

This is the simplest cost containment move. You maintain GLP-1 coverage for members with a confirmed type 2 diabetes diagnosis and exclude the weight-management indication. Your plan document and Summary Plan Description spell this out explicitly, and your PBM applies it at the point of dispensing.

The practical challenge is that many members with obesity also have comorbidities like pre-diabetes or metabolic syndrome that may qualify them for a diabetes indication. A strict diabetes-only policy will not eliminate GLP-1 utilization, but it meaningfully constrains it. Employers using this approach typically see GLP-1 pharmacy costs stabilize rather than accelerate, which is the goal going into renewal.

From an employee relations standpoint, this approach requires clear communication. Members who expected weight-management coverage and find it excluded at the pharmacy counter will have questions. A one-page benefits communication explaining what is covered and why, distributed at open enrollment, prevents a lot of friction.

Approach 2: Cover for Diabetes and Obesity with Prior Authorization

Prior authorization for GLP-1 drugs adds a clinical gatekeeping layer without eliminating the benefit entirely. The member's physician submits documentation confirming the diagnosis, BMI threshold, and any prior treatment history. The plan's pharmacy benefit manager or a clinical review vendor reviews the request and approves or denies it based on your plan's criteria.

This approach works well for employers who want to offer a competitive benefit but need to make sure utilization is clinically justified. Approval rates under a well-designed prior authorization program typically run 60 to 80 percent, meaning a meaningful share of requests are approved while those without qualifying diagnoses are filtered out.

The administrative burden here falls mostly on the PBM and the physician, not the employer. If your plan already uses prior authorization for other specialty drugs, adding GLP-1s to that workflow is straightforward. If you are a smaller group that has not used prior authorization much, your broker should be able to connect you with PBM vendors who handle the clinical review function on your behalf.

Approach 3: Exclude Weight Loss Indication, Add a Wellness Program

Some employers are pairing a GLP-1 exclusion for weight-management purposes with a funded wellness program that addresses the underlying health risks. The logic is straightforward: if employees cannot access GLP-1 drugs through the health plan for weight loss, offer them structured alternatives that have their own clinical evidence base.

Wellness programs in this context might include subsidized gym memberships, nutrition counseling, disease management programs for pre-diabetes, or on-site health coaching. These cost a fraction of a GLP-1 pharmacy benefit, and for a segment of the population, they produce meaningful outcomes without the open-ended drug cost.

The limitation of this approach is that GLP-1 drugs produce weight loss results that wellness programs typically cannot match for moderate to severe obesity. Some employees who genuinely benefit from GLP-1 therapy will see this as a reduction in their benefits. That trade-off is real, and employers using this approach should be transparent with their workforce about the reasoning.

What a Pharmacy Benefit Review Can Find Before Your Next Renewal

The Questions Your Broker Should Be Answering

A pharmacy benefit review is a systematic look at what your plan is spending on drugs, where the highest-cost claims are concentrated, how your formulary design is performing, and what changes could reduce cost without reducing clinical value. Every mid-size employer should have one before each renewal cycle. Most do not get one unless they ask for it specifically.

When it comes to GLP-1 coverage in particular, here are the questions your broker should be able to answer with data:

How many unique members in your plan had at least one GLP-1 claim in the last 12 months? What was the total plan cost for those claims? Were those claims under a diabetes indication, an obesity indication, or a mix? What prior authorization controls, if any, are currently in place? How does your GLP-1 spend per member compare to benchmark data for similar-sized employer groups?

If your broker cannot produce this data or does not have a clear framework for walking you through it, that is a signal worth paying attention to. The employers who are managing GLP-1 costs effectively in 2026 are the ones who went into their last renewal with their pharmacy claims data already organized, not the ones who discovered the issue after the carrier presented a 20 percent rate increase.

How Level-Funded Plans Give Employers More Flexibility

Fully insured plans give you very limited ability to modify benefit design between renewals. The carrier controls the formulary, the prior authorization criteria, and the cost-sharing structure. You can influence some of that through plan selection, but not much. When GLP-1 claims spike, you absorb the renewal increase and hope the carrier's formulary management catches up.

Self-funded and level-funded plan options work differently. The employer is the plan sponsor, which means the employer controls the plan document. You can add prior authorization requirements, carve out specific indications, set different formulary tiers, or work with a carve-out PBM for specialty drugs. That flexibility is valuable when a drug class like GLP-1 produces cost dynamics that did not exist three years ago.

Explore level-funded plan options if you are currently on a fully insured plan and want more control over how your pharmacy benefit is structured. Level-funded plans set a fixed monthly amount for expected claims, stop-loss coverage, and administration, giving you cost predictability while still allowing the kind of plan design flexibility that fully insured products do not offer.

For employers who want to take it a step further, self-funded captive health plans pool multiple employer groups together to share stop-loss risk, which gives smaller companies access to plan design flexibility and risk management tools that were previously only available to large self-insured corporations. If GLP-1 cost management is a priority, captive arrangements often allow for more nuanced pharmacy benefit design than standard level-funded products.

Frequently Asked Questions

Are employers required to cover GLP-1 drugs?

No. Employers that sponsor group health plans are not required by federal law to cover any specific drug or drug class, including GLP-1 medications. The ACA's essential health benefits requirements apply to individual and small group fully insured plans in a specific way, but mid-size and large employer-sponsored plans have significant flexibility in designing their pharmacy benefit. Your plan can legally exclude GLP-1 coverage entirely, limit it to specific diagnoses, or require prior authorization as a condition of coverage. That said, benefits decisions do affect recruiting and retention, so the business case for offering some form of GLP-1 coverage is worth considering alongside the cost data.

How much do GLP-1 drugs add to an employer health plan's annual cost?

It depends heavily on your workforce demographics and how broadly your plan covers the obesity indication. For a 100-person employer group with no prior authorization controls and open GLP-1 coverage, a 5 percent utilization rate at 500 dollars per member per month in net plan cost adds roughly 30,000 dollars per year to pharmacy spend. If utilization climbs to 8 or 10 percent, that figure moves to 48,000 to 60,000 dollars. These are approximations based on Milliman actuarial modeling of mid-size employer groups; your actual exposure depends on your workforce, plan design, and PBM contract terms.

Can I cover GLP-1 for diabetes but not for weight loss?

Yes. This is one of the most common plan design strategies mid-size employers are using right now. The plan document specifies that GLP-1 drugs are a covered benefit when prescribed for type 2 diabetes management, and explicitly excludes coverage for weight-loss or obesity indications. The PBM applies this distinction at the pharmacy level by requiring a qualifying diagnosis code as a condition of dispensing. It is a legally sound approach, and many carriers offer it as a standard formulary option. The key is making sure your PBM and your plan document language are aligned so the exclusion is consistently applied.

What is a prior authorization requirement and how does it work?

Prior authorization (PA) is a process where a prescription drug is covered by the plan only after the prescribing physician submits clinical documentation that a review body approves. For GLP-1 drugs, a typical PA process requires the physician to confirm the member's diagnosis (type 2 diabetes, obesity, or both), document the member's BMI meets the threshold in the plan criteria (commonly 30 or above, or 27 or above with a weight-related comorbidity), and in some cases confirm that other treatment options have been tried. The PBM or a third-party utilization management vendor reviews the submission, usually within 24 to 72 hours, and notifies the physician and member of the decision. PA does not eliminate coverage; it gates it to clinically appropriate use.

How do GLP-1 drugs affect stop-loss coverage?

Stop-loss carriers have become increasingly specific about GLP-1 coverage language in the last two renewal cycles. Some carriers are excluding GLP-1 weight-loss claims from counting toward the individual attachment point, which means those costs stay entirely with the employer no matter how high they climb. Others are adding laser provisions on members already enrolled in GLP-1 therapy at the time of stop-loss renewal, effectively setting a higher individual threshold for those specific members. Before your next stop-loss renewal, have your broker pull the contract language and identify any GLP-1 specific provisions. If your stop-loss carves out these drugs, your catastrophic cost protection has a gap you need to account for in your plan design decisions.

Is there a way to offer GLP-1 coverage without it becoming an open-ended cost?

Yes, and several approaches work in combination. Prior authorization limits coverage to members who meet clinical criteria. Indication-based coverage (diabetes only) keeps the eligible population defined. Step therapy requirements can require members to try lower-cost alternatives before GLP-1 approval. Quantity limits or duration limits can put a cap on continuous coverage periods, though duration limits for chronic conditions require careful legal review. Working with a carve-out PBM that specializes in specialty drug management gives you access to rebates and clinical management tools that standard carrier-bundled PBM contracts often lack. The combination of a well-drafted prior authorization policy and a strong PBM contract is where most mid-size employers are finding meaningful cost control without eliminating the benefit entirely.

References

1. Kaiser Family Foundation. 2024 Employer Health Benefits Survey. KFF, September 2024. https://www.kff.org/health-costs/report/2024-employer-health-benefits-survey/
2. Milliman. GLP-1 Cost Projection and Actuarial Impact Analysis for Self-Funded Employer Plans. Milliman Research, 2024. Available through Milliman.com actuarial publications.
3. Society for Human Resource Management. Managing Pharmacy Benefits in Employer Health Plans. SHRM, 2024. https://www.shrm.org/topics-tools/topics/benefits
4. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care, Volume 47, Supplement 1. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153944/Standards-of-Care-in-Diabetes-2024
5. Centers for Medicare and Medicaid Services. Drug Spending and Pricing Data: GLP-1 Receptor Agonists. CMS.gov, 2024. Available at cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/information-on-prescription-drugs.
6. NAPEO. PEO Industry Survey: Pharmacy Benefit Management Trends Among Mid-Market Employer Groups. National Association of Professional Employer Organizations, 2024. Available at napeo.org.